Salute e Benessere

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 12 March 2025 at 16.15 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly or through financial instruments by BlackRock, Inc. and its funds increased on 11...
Nasdaq GlobeNewswire
12/03/2025

Clinical Trial Services Market worth US$101.86 billion by 2030 with 8.9% CAGR |…

Browse in-depth TOC on "Clinical Trial Services Market" Browse in-depth TOC on "Clinical Trial Services Market" 661 - Tables 61 - Figures 521 - Pages By Based on Modality,the clinical trial services market is divided into small molecules, biologics, and medical devices. The large share of the small molecules clinical trial segment can be attributed to the established role of these drug modalities in drug development across various therapeutic areas. Small molecules have a...
PR Newswire
12/03/2025

Annual General Meeting 2025 – GN Store Nord A/S

/S held its Annual General Meeting. The Annual General Meeting was held in accordance with the agenda announced on February 17, 2025, as set out below.The report by the Board of Directors was noted by the general meeting. The Annual Report 2024 and the proposal on distribution of annual profits, including no distribution of dividends, were approved, and discharge was granted to the Board of Directors and the Executive Management.The general meeting approved the remuneration to the Board of...
Nasdaq GlobeNewswire
12/03/2025

OBI Pharma Receives 'Most Promising ADC Clinical Candidate in Taiwan' Award

Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation /12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma's achievement last year as a candidate in the World ADC Awards, where it was shortlisted among the top eight international pharmaceutical companies. The award further underscores the industry's acknowledgment of OBI Pharma's…
Nasdaq GlobeNewswire
12/03/2025

Endo Announces Peyronie's Disease Presentation at the Annual Meeting of the…

The Endo-supported research presentation is below: The Endo-supported research presentation is below: About the Post Hoc Phase 3 Data Analysis 1 A post hoc analysis of pooled data from two randomized, double-blind, placebo-controlled Phase 3 trials was conducted to evaluate CCH treatment and improvement in penile curvature in participants presenting with/without penile pain at baseline and disease duration of 12–18 months or >18 months. CCH-treated participants were stratified by...
PR Newswire
12/03/2025

Furniture Village shows that Britons are looking for minimalism, clean lines…

Experts at Furniture Village have explained why these dining room styles are so popular with Brits. Experts at Furniture Village have explained why these dining room styles are so popular with Brits. 1. Modern dining room - 3832 average monthly searches Made from sleek lines and using neutral tones, like greys and creams, it's no wonder modern dining rooms are the most searched-for style with 3832 monthly searches. An expert at Furniture Village says, "Many people choose to add touches...
PR Newswire
12/03/2025

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025– Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Wednesday, 9 April 2025, at 4 PM CEST at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda:The Board of Directors' report on the Company's activities in the past year. Presentation of the Annual Report for adoption. A proposal from the Board of...
Nasdaq GlobeNewswire
12/03/2025

MIND GAMES Makes Bold Move into UK Market with Exclusive Selfridges Partnership

This groundbreaking debut brings MIND GAMES' captivating fragrances to the discerning British market, offering an unparalleled olfactory experience that challenges conventional perfumery. This groundbreaking debut brings MIND GAMES' captivating fragrances to the discerning British market, offering an unparalleled olfactory experience that challenges conventional perfumery. The partnership between MIND GAMES and Selfridges represents a perfect alignment of values. Both brands are synonymous...
PR Newswire
12/03/2025

SKYLINEDX ANNOUNCES NEW STUDY DEMONSTRATING ENHANCED RISK STRATIFICATION FOR…

"This study underscores the transformative potential and the power of the Merlin test in accurately predicting the metastatic risk associated with complex head and neck melanomas," said Jvalini Dwarkasing, Chief Scientific Officer at SkylineDx. "By enhancing risk stratification, we can improve patient outcomes, optimize surgical procedures and utilization of healthcare resources. This advancement represents a significant step towards personalized melanoma care." "This…
PR Newswire
12/03/2025

Inaugural Global Longevity Summit Architects New Horizons In Human Health…

Informa Connect Medical Division announces landmark Geneva-based conference, convening the world's foremost industry leaders to forge strategic partnerships, accelerate breakthroughs, and fuse science, capital, and innovation. Convening a selected delegation of 300 innovators from 15+ nations, the Summit aims to accelerate global advancements in human health and longevity. By dismantling conventional silos that have long fragmented longevity research, the gathering ensures that…
Nasdaq GlobeNewswire
12/03/2025

Turacoz Group Leads the Future of Evidence Synthesis With AI-Powered Living…

The presentation explored how machine learning and automation transform evidence synthesis, enable real-time literature updates, and improve healthcare decision-making. Additionally, Turacoz shared findings from an HCP survey, assessing knowledge, attitudes, and practices related to living publications. The presentation explored how machine learning and automation transform evidence synthesis, enable real-time literature updates, and improve healthcare decision-making. Additionally, Turacoz...
PR Newswire
12/03/2025

Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and…

Financial terms of the agreement are not disclosed but include investment participation by Pierre Fabre Laboratories in RedRidge's Series A financing that will be announced separately, as well as upfront, milestone and future sales royalty payments in addition to funded research payments for Pierre Fabre Laboratories' worldwide program. RedRidge and Pierre Fabre Laboratories will share R&D costs for the co-development programs. Financial terms of the agreement are not disclosed but…
PR Newswire
12/03/2025

Philips highest ranked medical technology company among Clarivate Top 100 Global…

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has been recognized by Clarivate as the top-ranked medical technology company in theTop 100 Global Innovators 2025, reinforcing its global reputation as a leading healthcare innovator. A consistent high-performer, Philips has been included in this major assessment of global innovators for 12 consecutive years. Roy Jakobs, CEO of Royal Philips said: "At Philips,...
Nasdaq GlobeNewswire
12/03/2025

Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's…

"I am very happy and proud. It feels both exciting and honorable to receive this prize," says Lars Lannfelt, professor emeritus at Uppsala University and one of BioArctic's two founders. "I am very happy and proud. It feels both exciting and honorable to receive this prize," says Lars Lannfelt, professor emeritus atUppsala Universityand one of BioArctic's two founders. Lars Lannfelt succeeded in understanding what causes Alzheimer's disease as early as the 1990's. At the time…
PR Newswire
12/03/2025

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company as it advances pioneering kidney disease programmes into clinical development and explores potential partnershipsAppointment follows successful completion of Series B financing, raising $105 million, from a syndicate of high-quality investors Purespring is the first company to successfully treat kidney disease models by directly...
Nasdaq GlobeNewswire
12/03/2025

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of…

PARIS, FRANCE, March 12 th, 2025 -Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1 st, 2025. She will serve on Ipsen's Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen's global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic...
Nasdaq GlobeNewswire
12/03/2025

Zealand Pharma and Roche enter collaboration and license agreement to co-develop…

Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesityThe companies will co-develop and co-commercialize petrelintide monotherapy and potential combination products, including petrelintide/CT-388, in the U.S. and EuropeZealand Pharma will receive upfront cash payments of USD 1.65 billion, including USD 1.4 billion due at...
Nasdaq GlobeNewswire
12/03/2025

Roche enters into an exclusive collaboration & licensing agreement with Zealand…

Agreement allows for a range of potentially best-in-class therapy options as monotherapy and fixed dose combination with Roche`s lead incretin asset CT 388Collaboration will complement Roche's portfolio in the field of cardiovascular, renal, and metabolic (CVRM) diseasesObesity is a heterogeneous disease with over 200 related comorbidities, including cardiovascular and metabolic diseases, and is expected to impact over 4 billion people globally by 2035Basel, 12 March 2025 -...
Nasdaq GlobeNewswire
12/03/2025

XRP Healthcare Acquires Pharma Ville, a Retail and Wholesale Pharmacy Chain in…

With two retail pharmacies and five wholesale distribution centres strategically positioned across Uganda, Pharma Ville's established infrastructure enhances medicine accessibility nationwide. The acquisition strengthens XRP Healthcare's ability to streamline pharmaceutical supply chains and expand its footprint in Africa's healthcare market. With two retail pharmacies and five wholesale distribution centres strategically positioned acrossUganda, Pharma Ville's established infrastructure...
PR Newswire
12/03/2025

Tecan reports 2024 financial results, enhancing operational resilience amid…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports 2024 financial results, enhancing operational resilience amid challenging conditionsFinancial results for the full year 2024 – Highlights Sales of CHF 934.3 million (2023: CHF 1,074.4 million), down by -13.0% in Swiss francs and by -11.5% in local currencies; H2 sales decrease by -11.3% in local currenciesDecline in sales mainly due to softness in the instrument business with...
Nasdaq GlobeNewswire
12/03/2025

Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes…

Shilpa Medicare Ltd. had earlier completed phase-3 clinical studies of this novel product SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets - and presented the results of the trial titled, "A phase - III, Randomized, Double- Blind, placebo controlled, multicenter, Parallel group study", to evaluate the safety and efficacy of Nor-Ursodeoxycholic Acid 500 mg in patients suffering from Non-alcoholic Fatty Liver Disease to the SEC. Shilpa Medicare Ltd. had earlier completed phase-3…
PR Newswire
12/03/2025

TAGRISSO Sets the Stage for Market Leadership in Oncology with Strong Growth…

AstraZeneca's TAGRISSO (osimertinib) Overview AstraZeneca's TAGRISSO (osimertinib) Overview TAGRISSO is a prescription medication for adults with non-small cell lung cancer (NSCLC) that carries specific EGFR gene mutations. It is used to help prevent cancer recurrence after surgical tumor removal, as a first-line treatment for metastatic NSCLC, or for patients whose cancer has spread and no longer responds to prior EGFR TKI therapy. As a kinase inhibitor, TAGRISSO irreversibly targets...
PR Newswire
11/03/2025

BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market |…

Bristol Myers Squibb's BREYANZI (lisocabtagene maraleucel) Overview BristolMyers Squibb'sBREYANZI (lisocabtagene maraleucel) Overview BREYANZI is a CD19-targeting CAR T cell therapy that incorporates a 4-1BB costimulatory domain, which supports the expansion and longevity of CAR T cells. It is developed using a patient's own T cells, which are collected, genetically modified, and then infused as a one-time treatment. In the U.S., BREYANZI is approved for treating relapsed or...
PR Newswire
11/03/2025

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company…

Successful 2024 marked by significant clinical advancements across Oculis' late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS-05, in acute optic neuritis) and precision medicine (Licaminlimab, OCS-02, in dry eye disease) treatmentsRecent positive topline results in the ACUITY Phase 2 trial showed Privosegtor (OCS-05)'s neuroprotective benefits in anatomical preservation of the retina and visual...
Nasdaq GlobeNewswire
11/03/2025
Altri  Comunicati